We talk about on this show quite a bit.

We've been out ahead of really any other major media outlet when it comes to the adverse

reaction.

So we were on top of the even in the Johnson & Johnson's early trials.

They're thrombosis when those trials, I think it was a phase two clinical trial had to

be paused.

We were telling your audience about that.

The thrombosis, the myocarditis, the heart inflammation, the fainting, the bells palsy.

We were reporting on those all of those first.

And what's happening now is we have kind of a next generation, if you will, of adverse

events that are being seen in the medical literature.

And just to be clear, before we get into this segment, we're told again, fevers, chills,

a sore arm, that's really about it.

But that's where we're talking point is in the media.

Let's check out the medical literature.

This is one of the studies from, this isn't in the Scandinavian journal of immunology.

This was a Italian researcher.

And the title is Role of the Antigen Presentation Process Immunization Mechanisms of the Genetic,

those mRNA vaccines against COVID-19 and the need for bio-distribution evaluations.

Remember that's bio-distribution that Dr. Rose was talking about with those nanolipid

particles.

And it says here, up to now more than 1000 peer reviewed studies evidence a multitude

...